The bispecific antibodies market is expected to reach USD 5.6 billion by 2023 and is anticipated to grow at a CAGR of 9.5% during the forecast period 2023-2035

Bispecific antibodies (BsAbs) represent an increasingly prominent category of immunotherapeutic agents adept at simultaneously engaging two distinct antigens or discrete epitopes on the same antigen. These biologics function by activating immune effector cells to effectively combat cancerous cells through various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Importantly, bispecific antibody drugs showcase unique biological and pharmacological characteristics, available in a diverse range of formats, promising significant potential for therapeutic applications.

As of recent approvals, regulatory authorities have granted authorization for nine bispecific antibodies for therapeutic use, listed chronologically by their most recent endorsements: Tecvayli? (October 2022), Nanozora? (September 2022), AK104 (June 2022), Lunsumio? (June 2022), VABYSMO? (February 2022), KIMMTRAK? (January 2022), RYBREVANT? (May 2021), Hemlibra? (November 2017), and Blincyto? (December 2014). Furthermore, a notable surge in clinical trials investigating bispecific antibodies has emerged in recent years, driven by increasing favor and recognized therapeutic potential for such candidates. It is foreseeable that as more of these therapeutic contenders advance into clinical stages or gain regulatory endorsement, the market for bispecific antibody therapeutics is positioned for robust expansion and sustained growth.

Report Coverage
? The report conducts an analysis of the bispecific antibodies market, focusing on various aspects such as therapeutic area, mechanism of action, target antigen, antibody format, key players, and geographical regions.
? It evaluates factors influencing market growth, including drivers, restraints, opportunities, and challenges.
? The report appraises the potential advantages and hurdles in the market, providing insights into the competitive landscape for leading market players.
? Forecasts are made regarding revenue for market segments across four major regions.
? An in-depth examination of the bispecific antibodies market landscape is presented, encompassing approved, in-development, and preclinical stage antibodies. The report explores historical context, structural variations, mechanisms of action, and diverse applications of bispecific antibodies. It encompasses an analysis of over 220 existing antibodies and 180 in preclinical stages, considering developer details, developmental stages, target antigens, and therapeutic applications.
? It outlines current market trends through graphical representations, illustrating development phases, disease segments, and headquarters’ locations of these antibodies. Additionally, it evaluates more than 80 technology platforms used for bispecific antibody production, offering a comparative analysis based on development strength, company experience, size, and location.
? The report explores major pharmaceutical players in this sector, utilizing analyses like spider web and heat maps to assess competition, clinical trials, partnerships, and technology portfolios. Detailed profiles of key developers highlight their backgrounds, executive teams, financial information, drug portfolios, recent developments, and future prospects.
? Furthermore, it investigates partnerships within the domain, scrutinizing parameters such as partnership types, disease segments, payment models, deal amounts, and active players. It discusses challenges and considerations in the manufacturing process of bispecific antibodies, along with a list of pertinent contract manufacturing and research organizations.
? A comprehensive overview of ongoing and planned studies, regulatory guidelines by prominent agencies, and promotional strategies for approved antibodies like Blincyto? and Hemlibra? is provided. Finally, a market forecast analysis until 2035 presents sales projections based on therapeutic areas, mechanisms of action, target antigens, antibody formats, key players, and geographical regions.
? Summarizing industry trends, market drivers, and challenges within a SWOT framework provides a qualitative analysis using Harvey ball representations to delineate the relative impact of these parameters on the overall market.


Key Market Companies
? Akeso Biopharma
? Alexion
? Amgen
? Genmab
? Immunocore
? Janssen Research & Development
? Linton Pharm
? Merck
? OncXerna Therapeutics
? Pfizer
? Roche
? Taisho Pharmaceutical
? Zymeworks